GlassScriptPhysician profile
Shane F Laster
NPI 1215998331
$3,500.88
in general payments reported to CMS, 2019-2025
21 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.98 · 2020: $39.88 · 2021: $239 · 2022: $256 · 2023: $705 · 2024: $1,137 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762 · Long Term Medical Supply Or Device Loan: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,761.71 |
| Long Term Medical Supply Or Device Loan | $152.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $783.56 | 2024 | Optilight |
| Johnson & Johnson Vision Care, INC. | $524.17 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $473.14 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $327.18 | 2023-2025 | Miebo, Vyzulta |
| Alcon Vision LLC | $260.67 | 2023-2025 | Precision 1, Precision7, Total30 |
| Coopervision INC. | $232.85 | 2020-2025 | Biofinity Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Baxter Healthcare | $152.40 | 2025 | Hillrom - Spot Vision Screener |
| Tarsus Pharmaceuticals, INC. | $135.48 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $97.64 | 2022-2024 | Tyrvaya, Ryzumvi |
| Optos, INC. | $97.50 | 2021 | |
| Harrow Eye, LLC | $66.19 | 2024-2025 | Vevye |
| Abbvie INC. | $65.08 | 2022-2024 | |
| Dompe US, INC. | $42.67 | 2022-2025 | Oxervate |
| Abb Con-Cise Optical Group LLC | $38.05 | 2019-2024 | Spectacle Lenses, Contact Lens |
| Sun Pharmaceutical Industries INC. | $36.17 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $35.56 | 2022 | |
| Lkc Technologies, INC. | $31.06 | 2024 | |
| Allergan, INC. | $30.16 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $27.62 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.05 | 2023 | |
| Kala Pharmaceuticals, INC. | $19.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Laster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.